Integral Diagnostics Limited (ASX:IDX)
Australia · Delayed Price · Currency is AUD 2.440
+0.030 (1.24%)
Feb 26, 2026, 2:19 PM AEST
Integral Diagnostics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 767.82 | 627.22 | 469.7 | 440.76 | 360.93 | 350.7 | |
Revenue Growth (YoY) | 56.28% | 33.54% | 6.57% | 22.12% | 2.92% | 27.26% |
Cost of Revenue | 525.98 | 431.23 | 317.8 | 298.34 | 238.83 | 221.7 |
Gross Profit | 241.84 | 195.98 | 151.9 | 142.43 | 122.1 | 128.99 |
Selling, General & Admin | 40.65 | 33.91 | 25.75 | 23.39 | 21.17 | 19.64 |
Research & Development | 27.93 | 20.41 | 15.42 | 12.94 | - | - |
Amortization of Goodwill & Intangibles | 30.74 | 22.41 | 18.97 | 18.03 | 16.06 | 16.17 |
Other Operating Expenses | 30.79 | 26.59 | 20.7 | 22.3 | 26.24 | 22.98 |
Operating Expenses | 170.97 | 138.05 | 109.73 | 103.96 | 83.47 | 79.62 |
Operating Income | 70.88 | 57.93 | 42.17 | 38.47 | 38.62 | 49.37 |
Interest Expense | -33.92 | -28.77 | -22.31 | -18.3 | -10.48 | -8.82 |
Interest & Investment Income | 1.16 | 1.09 | 0.86 | 0.42 | 0.04 | 0.09 |
Earnings From Equity Investments | - | - | -0.06 | -0.33 | -0.16 | 0.02 |
Currency Exchange Gain (Loss) | - | - | - | - | - | 0.18 |
Other Non Operating Income (Expenses) | 12.96 | -0.13 | -0.23 | -0.05 | - | -0.09 |
EBT Excluding Unusual Items | 51.07 | 30.12 | 20.42 | 20.22 | 28.02 | 40.75 |
Merger & Restructuring Charges | -17.47 | -17.47 | - | 10.41 | -5.46 | -2.22 |
Impairment of Goodwill | - | - | -71.6 | - | - | - |
Asset Writedown | -0.54 | -0.54 | -3.04 | - | - | - |
Other Unusual Items | -8.6 | -1.21 | -2.92 | - | - | 6.7 |
Pretax Income | 25.22 | 11.66 | -57.14 | 30.63 | 22.56 | 45.22 |
Income Tax Expense | 11.03 | 6.84 | 3.56 | 5.59 | 7.96 | 13.95 |
Earnings From Continuing Operations | 14.19 | 4.82 | -60.7 | 25.04 | 14.6 | 31.27 |
Minority Interest in Earnings | -0.16 | -0.15 | - | - | - | - |
Net Income | 14.03 | 4.67 | -60.7 | 25.04 | 14.6 | 31.27 |
Net Income to Common | 14.03 | 4.67 | -60.7 | 25.04 | 14.6 | 31.27 |
Net Income Growth | 147.78% | - | - | 71.47% | -53.30% | 35.75% |
Shares Outstanding (Basic) | 369 | 307 | 233 | 233 | 209 | 198 |
Shares Outstanding (Diluted) | 374 | 310 | 233 | 236 | 212 | 200 |
Shares Change (YoY) | 55.38% | 32.86% | -0.97% | 11.29% | 5.70% | 7.16% |
EPS (Basic) | 0.04 | 0.02 | -0.26 | 0.11 | 0.07 | 0.16 |
EPS (Diluted) | 0.04 | 0.02 | -0.26 | 0.11 | 0.07 | 0.16 |
EPS Growth | 59.76% | - | - | 53.62% | -55.77% | 26.73% |
Free Cash Flow | 26.93 | 14.01 | 42.28 | 23.28 | 9.33 | 49.31 |
Free Cash Flow Per Share | 0.07 | 0.04 | 0.18 | 0.10 | 0.04 | 0.25 |
Dividend Per Share | 0.073 | 0.065 | 0.058 | 0.060 | 0.070 | 0.125 |
Dividend Growth | 25.86% | 12.07% | -3.33% | -14.29% | -44.00% | 31.58% |
Gross Margin | 31.50% | 31.25% | 32.34% | 32.31% | 33.83% | 36.78% |
Operating Margin | 9.23% | 9.24% | 8.98% | 8.73% | 10.70% | 14.08% |
Profit Margin | 1.83% | 0.74% | -12.92% | 5.68% | 4.05% | 8.92% |
Free Cash Flow Margin | 3.51% | 2.23% | 9.00% | 5.28% | 2.58% | 14.06% |
EBITDA | 106.72 | 86 | 66.22 | 66.08 | 62.22 | 72.59 |
EBITDA Margin | 13.90% | 13.71% | 14.10% | 14.99% | 17.24% | 20.70% |
D&A For EBITDA | 35.85 | 28.06 | 24.05 | 27.61 | 23.6 | 23.22 |
EBIT | 70.88 | 57.93 | 42.17 | 38.47 | 38.62 | 49.37 |
EBIT Margin | 9.23% | 9.24% | 8.98% | 8.73% | 10.70% | 14.08% |
Effective Tax Rate | 43.74% | 58.65% | - | 18.26% | 35.27% | 30.86% |
Revenue as Reported | 769.74 | 629.06 | 470.56 | 441.21 | 360.97 | 350.96 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.